India's recent landmark patent ruling correctly sets a high standard for innovative treatments, Cato Institute research fellow Swaminathan S. Anklesaria Aiyar writes. The court made it clear that it wasn't opposed to drug patents in general, he writes. PhRMA's Chip Davis called the verdict "another example of what I would characterize as a deteriorating innovation environment in India."

Full Story:

Related Summaries